Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT
Status:
Completed
Trial end date:
2022-06-02
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial was to assess the diagnostic performance and safety of Sodium
Fluoride F-18 Positron Emission Tomography / Computed Tomography (18F-NaF-PET/CT) in bone
metastases of malignant tumors compared with Technetium[99mTc] Methylenediphosphonate Bone
Scintigraphy ± Single Photon Emission Computed Tomography (99mTc-MDP-BS±SPECT).
The enrolled subjects were randomly assigned to two sequences A and B at a ratio of 1:1.
Within 7 days, 18F-NaF-PET/CT and 99mTc-MDP-BS±SPECT bone imaging were performed alternately.
The sensitivity, specificity, positive and negative predictive value of 18F-NaF-PET/CT and
99mTc-MDP-BS±SPECT were calculated respectively based on the diagnostic data of standard of
truth.